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Abrogation of ICOS/ICOS ligand (ICOSL) costimulation prevents the onset of diabetes 
in the non-obese diabetic (NOD) mouse but, remarkably, yields to the development of 
a spontaneous autoimmune neuromyopathy. At the pathological level, ICOSL−/− NOD 
mice show stronger protection from insulitis than their ICOS−/− counterparts. Also, the 
ICOSL−/− NOD model carries a limited C57BL/6 region containing the Icosl nul mutation, 
but, in contrast to ICOS−/− NOD mice, no gene variant previously reported as associated 
to NOD diabetes. Therefore, we aimed at providing a detailed characterization of the 
ICOSL−/− NOD model. The phenotype observed in ICOSL−/− NOD mice is globally similar 
to that observed in ICOS−/− and ICOS−/−ICOSL−/− double-knockout NOD mice, mani-
fested by a progressive locomotor disability first affecting the front paws as observed 
by catwalk analysis and a decrease in grip test performance. The pathology remains 
limited to peripheral nerve and striated muscle. The muscle disease is characterized by 
myofiber necrosis/regeneration and an inflammatory infiltrate composed of CD4+ T-cells, 
CD8+ T-cells, and myeloid cells, resembling human myositis. Autoimmune neuromyopa-
thy can be transferred to NOD.scid recipients by CD4+ but not by CD8+ T-cells isolated 
from 40-week-old female ICOSL−/− NOD mice. The predominant role of CD4+ T-cells 
is further demonstrated by the observation that neuromyopathy does not develop in 
CIITA−/−ICOSL−/− NOD in contrast to β2microglobulin−/−ICOSL−/− NOD mice. Also, the 
cytokine profile of CD4+ T-cells infiltrating muscle and nerve of ICOSL−/− NOD mice is 
biased toward a Th1 pattern. Finally, adoptive transfer experiments show that diabetes 
development requires expression of ICOSL, in contrast to neuromyopathy. Altogether, 
the deviation of autoimmunity from the pancreas to skeletal muscles in the absence 
of ICOS/ICOSL signaling in NOD mice is strictly dependent on CD4+ T-cells, leads to 
myofiber necrosis and regeneration. It provides the first mouse model of spontaneous 
autoimmune myopathy akin to human myositis.
Keywords: autoimmunity, type 1 diabetes, neuropathy, myopathy, costimulation, icOs, icOsl
Abbreviations: ALN, axillary lymph nodes; β2-m, beta-2-microglobulin; T1D, type 1 diabetes; ICOSL, ICOS ligand; MP0, 
myelin protein zero; PLN, pancreatic lymph nodes; PNS, peripheral nervous system, SPL, spleen; QTLs, quantitative trait loci.
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inTrODUcTiOn
Type 1 diabetes (T1D) is an autoimmune disease characterized 
by the activation of autoreactive lymphocytes against pancreatic 
β-cell antigens. Mechanisms that initiate the failure of immune 
tolerance to β-cells remain elusive in common forms of T1D (1, 2).
In animal models such as the non-obese diabetic (NOD) 
mouse, the predominant role of T-cells is supported by experi-
ments in which diabetes is transferred into naive recipients by 
T-cells from diabetic or prediabetic animals (3). Moreover, T1D 
is prevented by injection of antibodies (Abs) that interfere with 
T-cells activation and fails to develop in diabetes-prone mice 
in which key genes in T-cells differentiation or activation are 
non-functional (4, 5). Both CD4+ and CD8+ T-cells are involved 
in diabetes development and both major histocompatibility 
complex (MHC) class I- and class II-knockout NOD mice fail to 
develop diabetes (6, 7). The activation of autoreactive T-cells in 
diabetes requires the recognition of auto-antigens expressed by 
β-cells as well as costimulatory signals (8). Membrane proteins 
of the Cd28 gene family mediate costimulatory signals through 
their interaction with members of the B7 family expressed on 
antigen-presenting cells and stromal cells (9). In vivo deletion of 
the Cd28 or B7 genes and Icos or Icosl genes profoundly affects 
the development of diabetes in the NOD mouse by modulating 
effector and/or regulatory T-cells (10–14).
NOD mice, as humans, are susceptible to the development of 
other forms of autoimmunity and occasionally develop infiltrates 
in the thyroid, the parathyroid, the adrenal, and salivary glands (4, 
15–17). This predisposition to autoimmunity also sets up NOD 
mice as a relevant model for experimental induction of autoim-
mune diseases such as autoimmune prostatitis or autoimmune 
thyroiditis (16, 18, 19). Different NOD genes are involved in ori-
enting the autoimmune response toward β-cells. The main region 
controlling the targeting of β-cells is the MHC, but other regions 
have been evidenced in double congenic mice (20–24). Finally, 
genes controling costimulatory T-cells molecules have been 
shown to play a key role in directing autoimmunity, as observed 
in B7.2-knockout NOD mice, which fail to develop diabetes but 
develop autoimmune peripheral neuropathy (25, 26).
We previously reported that protection from diabetes in 
ICOS−/− NOD mice was unexpectedly associated with the develop-
ment of an autoimmune disorder of the neuro-muscular system, 
characterized by myositis and sensory ganglionitis. In this model, 
defective activation of diabetogenic effector ICOS−/−T-cells and 
a defect in Treg cells result in the protection of ICOS−/− NOD 
mice from diabetes (14). Here, we focused on ICOSL−/− NOD 
mice which, in contrast to ICOS−/− NOD mice, only carry in their 
genome a limited C57BL/6 region containing the Icosl nul muta-
tion but no gene variant previously reported as associated to NOD 
diabetes. This study describes the autoimmune neuromyopathy 
that predominantly occurs in females and manifests clinically by 
locomotor disability first affecting the front paws. We show that 
neuromuscular autoimmunity is associated to a CD4+ Th1 profile, 
fails to develop in mice lacking CD4+ but not CD8+ T-cells, and 
is transferable by CD4+ T-cells. This definitively demonstrates 
the autoimmune character and MHC class II restriction of the 
neuromyopathy.
aniMals anD MeThODs
Mice
NOD mice were bred and housed in our facilities under specific 
pathogen-free conditions. ICOS−/− and ICOSL−/− NOD mice were 
generated as described previously (14).
ICOS−/−ICOSL−/− NOD mice were established by crossing 
ICOS−/− NOD with ICOSL−/− NOD mice to generate F1 mice, 
and F1 mice were repeatedly intercrossed together to produce 
homozygous mice.
CIITA−/−ICOSL−/− and β2microglobulin (β2m)−/−ICOSL−/− 
NOD mice were established similarly by crossing ICOSL−/− NOD 
mice with CIITA−/− NOD mice and β2m−/− NOD mice (Jackson 
laboratory, Bar Harbor, ME, USA), respectively. ICOSL−/− 
NOD.scid mice were obtained by crossing NOD.scid mice with 
ICOSL−/− NOD mice. The prevalence of diabetes in our NOD 
colony reaches 10% in males and 60% in females by 6 months of 
age. Animal studies were approved by institutional review.
genetic analysis
Genomic DNA extracted from mouse tail tips using standard 
protocols was processed and hybridized on Affymetrix Mouse 
Diversity Genotyping Arrays (Santa Clara, CA, USA) according 
to the manufacturer’s instructions. For data extraction, genome 
coordinates were determined using the assemblies UCSC version 
mm10 and NCBI version GRCm38. Non-informative markers 
were manually removed for further comparative strain analysis. 
In all, 56,690 markers were evaluated for the ICOS−/− NOD mice, 
558,318 for the ICOSL−/− NOD mice when compared to NOD 
mice.
Diabetes and neuromyopathy 
assessments
Diabetes was assessed by monitoring mice as described previ-
ously (14). Neuromyopathy was quantified using a clinical score 
as follows. Stage 1 is defined by asymmetric extension of back legs 
after tail-suspension test. Stage 2 is defined by retraction of back 
legs after tail-suspension test. Stage 3 is defined by flexion of front 
and back legs without snatching to the grid after tail-suspension 
test.
Weight variations were monitored longitudinally, and muscle 
strength was assessed by grip test performance (Bioseb) on the 
front paws. Locomotor activity was analyzed using a Catwalk 
apparatus (Noldus) comprising a high-speed color camera for 
accurate spatial and temporal resolution, real-time movement 
recording, and automated analysis of the locomotor ability.
histological analysis
Gastrocnemius were dissected and frozen in cold isopentane. 
Sections of 4  μm from these muscles were then stained with 
hematoxylin and eosin. Immunohistochemistry was performed 
on frozen muscle sections using the Vectastain elite ABC per-
oxidase kit (Vector). Sections were stained with primary Abs 
directed against CD4 (GK1.5), CD8 (53-6.7), F4/80 (BM8) from 
eBioscience, CD11b (M1/70) from BD Pharmingen, or MYH3 
(F1.652) from Santa Cruz Biotechnology, then revealed with an 
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appropriate secondary antibody if necessary and streptavidin-
peroxydase using amino-ethyl-carbazole (Vector) as substrate.
Alternatively, anesthetized animals were perfused with 
a 4% formaldehyde solution (Electron Microscopy Science, 
Hatfield, PA, USA), then brain, spinal cord, spinal roots, spinal 
and trigeminal ganglia, and pieces of different skeletal muscles 
were dissected and embedded into paraffin. Three sections were 
stained with hematoxylin and eosin. Immune infiltration was 
estimated and graded from 0 to 3. Immunocytochemistry was 
performed on frozen muscle preparations. Sections were stained 
with primary antibody specific to: CD8 (53-6.7), CD4 (RM4-5), 
I-Ad (AMS-32.1), H-2Kd (SF1-1.1), CD11b (M1/70), or CD45R/
B220 (RA3-6B2) from BD Bioscience. Histologic sections were 
labeled with a secondary antibody (Anti-rat biotin from eBiosci-
ence and/or streptavidine-594 from Invitrogen), and cell nuclei 
were counterstained using Hoechst.
antibody isotype Quantification
Maxisorp plates were coated using one of the following Abs: anti-
IgG1, anti-IgG2a, anti-IgG2b, anti-IgG3, anti-IgM (Southern 
Biotech). After incubation with mouse sera, revelation was 
performed using biotin-coupled anti-mouse immunoglobulin 
(Ig) (H +  L) (Jackson IR), streptavidin HRP (ThermoFisher), 
TMB, and H2SO4. Optical densities were assessed using a 
ThermoScientific Multiskan FC apparatus.
Flow cytometry analysis
Antibodies
The following Abs were used purified or conjugated to biotin 
(hybridoma clone indicated in parentheses): CD4 (RM4-5), CD8 
(53-6.7), B220 (RA3-6B2), CD11b (ICRF44), CD11c from BD 
Bioscience and IFN-γ (4S.B3), IL-4 (B-S4), IL-17 (17B7), FOXP3 
(FJK-16s), and ICOSL (HK5.3) from eBioscience. Appropriate 
isotype control mAbs were included. Living cells were gated on 
side scatter versus forward scatter density plot.
Immunofluorescence Staining
Immunofluorescence staining was performed as described 
previously (14). Intracellular cytokine staining was performed 
according to the manufacturer’s instructions (staining intracel-
lular antigens; eBioscience). Flow cytometryc analyses were 
performed with a FACS FORTESSA (Becton Dickinson), using 
the FlowJo software (Tree Star, Ashland, OR, USA).
Cytokine Production
5 × 104 CD4+ T-cells from 8-week-old ICOSL+/+ or ICOSL−/− NOD 
mice were cultured in triplicate in 96-well plates with 1 × 105 irra-
diated NOD splenocytes, phorbol 12 myristate 13-acetate (PMA 
10 ng/ml; Sigma), ionomycin (1 μg/ml; Sigma), and brefeldin A 
(10 μg/ml; Sigma). CD4+ T-cells were incubated 4 h at 37°C. Cells 
were collected and tested for IFN-γ, IL-4, and IL-17 production 
by flow cytometry gated on CD4+ T-cells.
immunomagnetic cell sorting
CD4+ T-cells were obtained using mouse CD4− Negative Selection 
Kit (Invitrogen Dynal AS, Carlsbad, CA, USA), according 
to the manufacturer’s instructions. CD8+ T-cells/CD4+ and 
CD8+ T-cells/CD4+CD25+ T-cells or CD4+CD25− T-cells were 
positively selected by MACS sorting with biotinylated anti-CD4 
and/or anti-CD8 Abs, biotin-anti-CD25 (BD Bioscience) Abs 
using LS or LD columns and streptavidin beads according to the 
manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, 
Germany).
adoptive cell Transfer
Purified CD4+ T-cells, CD8+ T-cells, T-cells including CD4+ 
T-cells and CD8+ T-cells, splenocytes depleted of CD4+ and CD8+ 
T-cells from 8 or 40-week-old either ICOSL+/+ or ICOSL−/− NOD 
mice were selected as described above. When indicated, cells 
were then stimulated with 1 μg/ml anti-CD3 (BD Bioscience) 
and anti-CD28 (BD Bioscience) for 48 h. IL-2 (20 U/ml, R&D 
Systems, Minneapolis, MN, USA) was added to the culture 
of the splenocytes depleted of CD4+ and CD8+ T-cells. Total 
spleen (SPL) cells or purified T-cells, stimulated or not, were 
then adoptively transferred i.v. into 6- to 8-week-old ICOSL+/+ 
or ICOSL−/− NOD.scid mice as previously described (14). Ten 
days after transfer and up to 15 weeks post-transfer, mice were 
tested twice a week for glycosuria and neuromyopathy scored. 
Anesthetized mice were then perfused intracardially by 4% 
formaldehyde solution, in order to perform histological analysis 
(Electron Microscopy Science, Hatfield, PA, USA).
Quantitative rT-Pcr experiments
Total RNA from cultured mouse brain, spinal cord, muscle, 
lymphoid cells, and Schwann cell line (MSC80) were obtained 
using TRIzol® Reagent (Invitrogen, France). One microgram of 
total RNA was reverse transcribed with random primers from 
Promega (Charbonnières, France) and reverse transcriptase 
M-MLV-RT from Invitrogen (Cergy Pontoise, France).
Quantitative real-time PCR was performed with standard pro-
tocols using SYBR®Green ROX Mix (Thermo Scientific, France) 
as a fluorescent detection dye in ABI PRISM® 7000 in a final 
volume of 10 μl which also contains 300 nM primers (Operon, 
Germany) and 20  ng of reverse transcribed RNA in 384-well 
plates. To characterize the generated amplicons and to control 
the contamination by unspecific by-products, a melting curve 
analysis was employed. Each reaction was performed in tripli-
cate, and the mean of at least three independent experiments was 
calculated. All results were normalized to the 26S mRNA level 
and calculated using the Delta Ct method. The primer sequences 
used in real-time qPCR are:
iCOS F = TAGGGTGTGCAGCTTTCGTT
iCOS R = AGCTTATGAGGTCACACCTGC
iCOSL F = CAGCGGCATTCGTTTCCTTC
iCOSL R = GTCAGGCGTGGTCTGTAAGT
statistical analysis
Appropriate statistical tests (log rank or student t test) were 
performed as indicated in figure legends using GraphPad 
Prism Version 4.0b software (GraphPad Software, La Jolla, 
CA, USA).
Table 1 | size of the non-nOD-derived genomic regions around the 
mutated genes expressing icOs and icOs/icOs ligand in non-obese 
diabetic congenic mice, and comparison of these intervals to known 
candidate regions for type 1 diabetes (Idd loci) and neuropathy (QTls).
base pairs Idd/marker
intervals of the Idds
chr1 60,826,239 62,793,632 Idd5.1
66,483,902 70,037,817 Idd5.3
73,937,554 75,468,438 Idd5.2
non-nOD interval of the Icos−/− knockout
chr1 3,544,819 7,501,347 rs31808238 rs36471198
non-nOD snPs containing intervals in the Icosl−/− knockout
chr 10 74,298,599 75,507,309 rs51825371 rs13471390
84,580,657 85,644,817 rs29371540 rs51263527
86,197,418 86,437,612 rs30182742 rs30196734
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ethics approval
This study was carried out in accordance to the recommendations 
of Institutional Animal Care and Use Guidelines. The protocol 
was approved by the ethic committee under number CEEA34.
CB.024.11.
resUlTs
genetic characterization of icOs−/− and 
icOsl−/− nOD Mice
To study the role of the ICOS costimulation pathway in NOD 
mice, we initially used ICOS−/− or ICOSL−/− animals that were 
backcrossed onto a NOD genetic background. In ICOS−/− NOD 
mice, we detected a large interval of 39.6 Mb between the markers 
rs31808238 and rs36471198 almost entirely composed of SNPs of 
non-NOD origin (data not shown). This interval overlaps with 
the Idd regions 5.1, 5.2, and 5.3 (Table 1). However, Idd5 has been 
experimentally excluded to have any effect on neuropathy (26).
In the ICOSL−/− strain, we detected an interval of 1.2  Mb 
around the Icosl gene (rs51825371 to rs13471390), that was less 
than half, but not entirely, composed of non-NOD alleles (data 
not shown). In addition, two distal intervals of 1.1 Mb and 240 kb 
with similar composition were detected between the markers 
rs29371540 and rs51263527, and rs30182742 and rs30196734, 
respectively (Table 1). All three intervals do not overlap with any 
known Idd intervals. They do also not correspond to previous QTL 
locations for neuropathy on chromosome 10, e.g., Annp9 that has 
been mapped further proximal at the marker rs13480629 (chr 10; 
67,011,671 bp) (27). Therefore, we chose to study ICOSL−/− rather 
than ICOS−/− NOD mice in this report.
icOs−/−, icOsl−/−, and icOs−/−icOsl−/− 
Double-Knockout nOD Mice are 
Protected from T1D and Develop 
neuromuscular autoimmunity
As we previously reported, both ICOS−/− and ICOSL−/− NOD 
mice are protected from diabetes but develop a severe neuro-
myopathy (14). As shown in Figure 1A, diabetes developed from 
the age of 12 weeks in female wild-type (WT) ICOSL+/+ NOD 
mice and reached a plateau at around 32  weeks of age with a 
final prevalence of diabetes of 65% at 50 weeks. At 24 weeks of 
age, ICOSL−/− NOD mice remained free of insulitis with very few 
lymphocytes seen in the periphery of the islets, in contrast with 
ICOS−/− NOD mice in which a peri-insulitis was still observed 
(data not shown). Female ICOSL−/− NOD mice developed clinical 
neuromuscular disease from 19 weeks to reach a plateau around 
34 weeks of age. Overall, the timescale of neuromyopathy onset 
paralleled that of diabetes with a 6–8 weeks delay (p = 0.01; Log-
Rank Test). However, if the prevalence of diabetes reached 65% 
by 50 weeks of age in ICOSL+/+ NOD female mice, the prevalence 
of neuromyopathy was 100% in female ICOSL−/− NOD mice 
(Figure 1A) and 60% in male ICOSL−/− (not shown) by 50 weeks 
of age. We then compared female ICOS−/− and ICOSL−/− NOD 
mice and addressed whether the incidence was comparable in 
ICOS−/−ICOSL−/− double-knockout mice. ICOS−/−, ICOSL−/−, 
and ICOS−/−ICOSL−/− NOD mice were all protected from 
diabetes and developed neuromyopathy following similar 
survival curves, but median age of neuropathy was younger 
in ICOSL−/− (22 weeks) versus ICOS−/− NOD mice (30 weeks, 
p = 0.008) (Figure 1B). ICOS+/+ICOSL−/− NOD mice presented a 
significant loss of grip strength at 34 weeks of age as compared to 
ICOS+/+ICOSL+/+ NOD mice (Figure 1C) and a significant loss 
of weight at 43 weeks of age (Figure 1C). Locomotor disability 
first affected the front paws in ICOS+/+ICOSL−/− NOD mice, as 
manifest by reduction in print area and paw contact intensity 
(Figure 1D). Heterozygous ICOSL± NOD females maintained a 
high prevalence of diabetes (71%, n = 20/28) and, when remain-
ing diabetes-free, developed neuromyopathy (87%, n =  7/8 at 
30 weeks) (data not shown).
On histological sections, muscle and nerve infiltrates were 
already present in 24-week-old female mice but were not 
detected in 16-week-old female mice (data not shown). The 
severity of the neuromuscular infiltrate was identical in female 
ICOS+/+ICOSL−/− and ICOS−/−ICOSL−/− NOD mice (Figure 1E). 
High grade immune infiltration was detected in muscles and 
peripheral nerves of 40-week-old female ICOS+/+ICOSL−/− NOD 
mice (Figure 1F) but also in male ICOS+/+ICOSL−/− NOD mice 
despite the lower prevalence of clinical neuromuscular disease 
(data not shown). Muscular infiltration was associated with 
evidence of necrosis and regeneration and composed of CD4+ 
T-cells, CD8+ T-cells, F4/80+ macrophages, and CD11b+ myeloid 
cells (Figure 1F). At 24 weeks of age, it was possible to recover 
infiltrating cells from muscles of ICOSL−/− NOD mice and to 
analyze by flow cytometry the composition of the infiltrate: 31% 
B220+ cells, 26% CD8+ T-cells, and 54% CD4+ T-cells among 
TCR+T-cells, with 7% of CD4+Foxp3+ T-cells among CD4+ 
T-cells (data not shown).
immune Phenotype of icOsl−/− nOD Mice
We further studied the CD11b+ cells, CD4+ T-cells, CD8+ T-cells, 
and B220+ cells in axillary lymph node (ALN), pancreatic lymph 
node (PLN), and SPL in ICOSL−/− NOD mice as compared to WT 
NOD mice at 6 weeks of age. These populations were comparable 
in ICOSL−/− NOD mice and in WT NOD mice (Figure  2A). 
Interestingly, a reduction of 25–32% FOXP3+CD25+CD4+ 
T-cells was seen in ICOSL−/− mice as compared to WT mice, 
FigUre 1 | continued
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respectively, in PLN and SPL (Figure 2A). Cytokine production 
by CD4+ T-cells was analyzed by flow cytometry following PMA-
ionomycin activation. The IFN-γ, IL-4, and IL-17 production 
were not different in ICOSL−/− NOD mice and ICOSL+/+ NOD 
mice in SPL or lymph node (Figure 2B). But strikingly muscle 
and nerves infiltrating T-cells from 40-week-old ICOSL−/− NOD 
mice produced INF-γ but not IL-4 or IL-17 after PMA-ionomycin 
stimulation (Figure 2C).
Because ICOS is expressed by follicular helper T-cells that 
are involved in the class switch from IgM to IgG subclasses, 
we investigated whether serum Ig isotypes could be affected 
in ICOSL−/− NOD mice. Before neuromuscular disease onset 
(8 weeks), we only observed a slight decrease in total Ig amount 
in ICOSL−/− NOD mice sera as compared to ICOSL+/+ NOD mice 
(Figure 2D). Yet, there was no difference in Ig subclasses between 
ICOSL−/− NOD and ICOSL+/+ NOD mice. Also, when disease was 
apparent at 25 weeks, no difference between the ICOSL−/− and 
ICOSL+/+ NOD mice was either observed, except a minor varia-
tion in IgG2a levels (Figure 2E). Therefore, the neuromyopathy 
developed by ICOSL−/− NOD mice is very unlikely to be linked 
to a default in Ig switch.
Because ICOSL is constitutively expressed on antigen-present-
ing cells, we studied its expression in B-cells, dendritic cells, and 
myeloid cells of our mice. ICOSL was present at the surface of 
about 20% of B-cells, myeloid, and dendritic cells in pancreatic 
and ALN cells of 6-week-old ICOSL+/+ NOD mice. In the SPL, 
FigUre 1 | icOs−/−, icOsl−/−, and icOs−/−icOsl−/− double-knockout non-obese diabetic (nOD) mice are protected from T1D and develop 
neuromuscular autoimmunity. (a) Incidence of clinical neuromyopathy (◾) and diabetes (◽) in female ICOSL−/− NOD mice (n = 18 mice) and incidence of 
neuromyopathy (▴) and diabetes (Δ) in female ICOSL+/+ NOD mice (n = 20 mice) (Log-Rank Test). (b) Spontaneous Incidence of clinical diabetes and 
neuromyopathy in female ICOS−/− ICOSL+/+ (◾, n = 11), ICOS+/+ICOSL−/− (▴, n = 10), ICOS−/−ICOSL−/− (⦁, n = 13), and ICOS+/+ICOSL+/+ NOD mice (▿, n = 14) 
(Log-Rank Test). (c) Functional impairment in ICOSL−/− NOD mice. Muscle strength assessed by grip test performance in ICOS+/+ICOSL−/− (black, n = 6) and 
ICOS+/+ICOSL+/+ NOD mice (white, n = 5) (Student t-test). Weight variations in female ICOS+/+ICOSL−/− (▴, n = 5) and ICOS+/+ICOSL+/+ NOD mice (▿, n = 3).  
(D) Locomotor activity assessed by catwalk analysis. Cadence (steps/s), print area (cm2), and paw contact intensity (%) were assessed in 35-week-old female 
ICOS+/+ICOSL−/− (black, n = 10) and ICOS+/+ICOSL+/+ NOD mice (white, n = 15) (Student t-test). (e) Histologic score of the cell infiltrate in peripheral nerve system, 
muscle, and brain in female ICOS+/+ICOSL−/− and ICOS−/−ICOSL−/− NOD mice. (F) Representative sections of gastrocnemius from 34-week-old female ICOSL−/− and 
ICOS+/+ICOSL+/+ NOD mice. Hematoxylin/eosin (H&E) stainings showing an endomysial mononuclear infiltrate and necrotic myofibers. MYH3 immunostainings 
highlight regenerating myofibers, and immunostaining for CD4+, CD8+ T-cells, F4/80+ macrophages, and CD11b+ myeloid cells within infiltrates.
6
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ICOSL was expressed on almost 50% of B-cells, 40% of myeloid 
cells, and 21% of dendritic cells (Figure 2F). Regarding mRNA 
expression, Icos and Icosl, were expressed in brain, in spine but 
not Schwann cells of control mice. In muscle, mRNA expression 
was found very low (Figure 2G).
The neuromyopathy is a cD4+ T cell-
Dependent autoimmune Disease
In order to address whether the neuromuscular syndrome 
observed in ICOSL−/− NOD mice was dependent on both CD4+ 
and CD8+ T-cells, as seen for diabetes, or on either of these two 
subsets, we performed adoptive transfer experiments. When 
CD4+ T-cells were transferred in association with CD8+ T-cells 
from diseased ICOSL−/− NOD mice or even as a single subset 
into NOD.scid recipient mice, both recipient groups developed 
neuromyopathy but not diabetes. Development of clinical neu-
romyopathy was observed as early as by 25  days post-transfer 
and in 80–100% recipients within 50  days post-transfer. By 
contrast, ICOSL−/− CD8+ T-cells alone or splenocytes depleted in 
CD4+ T-cells and CD8+ T-cells (CD4−CD8− T-cells) did transfer 
neither neuromyopathy nor diabetes (Figure 3A). Histological 
analyses of recipient mice confirmed that either CD4+ T-cells 
or CD4+ T-cells in association with CD8+ T-cells transfer a neu-
romuscular infiltrate in NOD.scid recipients (Figure  3B). The 
composition of the infiltrate observed in muscles and nerves was 
identical to that observed in the spontaneously diseased mice 
(data not shown).
To confirm that autoimmune neuromyopathy develop-
ment in ICOSL−/− NOD mice was CD4+ T  cell-dependent, we 
studied ICOSL−/− NOD mice that were further deficient in 
either the C2ta or the β2-m genes. These mice were deprived 
of either class II-restricted CD4+ T-cells or class I-restricted 
CD8+ T-cells, respectively. ICOSL−/−CIITA−/− NOD mice did 
not develop autoimmune neuromyopathy, in contrast to control 
ICOSL−/−CIITA+/+ NOD mice (Figure 3C). They did not develop 
diabetes over 40 weeks of survey (data not shown). By contrast, 
ICOSL−/−β2-m−/− NOD mice developed a neuromyopathy, along 
with a neuromuscular infiltrate that was comparable to that devel-
oped by ICOSL−/− β2m+/+ control NOD mice (Figure 3D). Thus, 
both ICOSL−/−CIITA−/− and ICOSL−/−β2m−/− NOD mice were 
protected from diabetes, but only ICOSL−/−CIITA−/− NOD mice 
FigUre 2 | continued
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were protected from neuromuscular autoimmunity, confirming 
the major pathogenic role of CD4+ T-cells in the neuromuscular 
model.
We further investigated whether muscle- and nerve-infil-
trating cells were able to directly transfer nerve and/or muscle 
autoimmunity. We isolated muscle and nerve infiltrates and 
transferred them into NOD.scid mice. Recipients developed 
clinical neuromyopathy following the transfer of either nerve 
(two recipient mice out of three) or muscle (six recipient mice 
out of seven) infiltrating T-cells. Nerve-infiltrating T-cells 
induced nerve and muscular infiltrates in NOD.scid recipients, 
although, the number of infiltrating cells recovered from nerve, 
and transferred (0.2 × 106) was fivefold lower as compared to cells 
recovered from infiltrated muscle and transferred into NOD.scid 
recipients (1.0 × 106) (Figure 3E).
icOs/icOsl is not required for efficient 
Transfer of neuromyopathy
The ICOS/ICOSL pathway has been shown central in the 
primary activation of naive T-cells (28). Whether it is also 
required for activation of autoreactive effector cells remains 
an open issue. CD8+ T-cells and CD4+ T-cells from aging 
conventional or ICOSL+/+ NOD mice directly transfer diabetes 
into NOD.scid recipients without the need of prior in  vitro 
activation. However, it has been observed that the transfer of 
FigUre 2 | immune phenotype of icOsl−/− non-obese diabetic (nOD) mice. (a) Percentage of CD4+, CD8+, B220+, CD11b+, and CD4+FOXP3+ cells in 
spleen (SPL), axillary lymph node (ALN), pancreatic lymph node (PLN), and SPL of ICOSL+/+ and ICOSL−/− NOD mice at 6-week-old (n = 6, NS: p > 0.05, 
Mann–Whitney test). (b) IFN-γ, IL-4, and IL-17 cytokine production by CD4+ T-cells from lymph node, SPL after PMA iomonycine stimulation. (c) IFN-γ, IL-4, and 
IL-17 cytokine production by CD4+ T-cells infiltrating muscle and nerves of ICOSL−/− NOD mice after PMA iomonycine stimulation (NA, non-activated). Data are 
representative of three independent experiments. Immunoglobin isotypes levels in sera from 8-week-old mice, before neuromuscular disease onset (D) and from 
25-week-old mice (e) in ICOSL−/− and ICOSL+/+ NOD mice (n = 5, NS: p > 0.05, *p < 0.05 **p < 0.005, Mann–Whitney test). (F) Expression of ICOS/ICOS ligand 
(ICOSL) on B220+, CD11c+, and CD11b+ cells in ALN, PLN, and SPL of 6-week-old ICOSL+/+ NOD mice (n = 6, *p < 0.05, **p < 0.005, Mann–Whitney test). 
(g) Icos and Icosl expression on brain, Schwann cells, spine, and muscle of control mice (Mann–Whitney test).
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FigUre 3 | continued 
neuromyopathy is cD4+ T cell-dependent. (a) Transfert of spleen (SPL) T-cells from ICOSL−/− old mice into non-obese diabetic (NOD).scid mice. Eight-week-old 
female NOD.scid recipient mice were transferred with 0.8 × 106 stimulated CD4+ T-cells (◾), 0.8 × 106 stimulated CD8+ T-cells (ν), 0.8 × 106 purified stimulated T-cells 
including CD4+ and CD8+ T-cells (▴), or 0.8 × 106 stimulated splenocyte depleted of CD4+ and CD8+ T-cells called “CD4− CD8−” (▾) from 40-week-old ICOSL−/− 
NOD mice (n = 6, data are representative of three independent experiments). (b) Histological scores of infiltrating cells in muscle and peripheral nervous system of 
transferred recipients. (c) Incidence of neuromyopathy in ICOSL−/−CIITA−/− NOD mice. (D) Incidence of neuromyopathy in ICOSL−/−beta2m−/− NOD mice.  
(e) Histological scores of infiltrating cells in muscle and peripheral nervous system of recipient mice after transfer of T-cells isolated from muscles (106 cells) and 
nerves (0.2 × 106 cells) of 40-week-old ICOSL−/− NOD mice.
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diabetes is delayed by treatment of recipients mice by anti-class 
II monoclonal Abs (29), indicating that interactions between 
CD4+ effector T-cells and APCs through class II-mediated 
antigen presentation is still required for efficient transfer. In case 
of autoimmune neuromyopathy, the need for pre-activation of 
effector T-cells in vitro using anti-CD3 and anti-CD28-coated 
microplates prior to transfer has been reported when transfer-
ring autoimmune peripheral neuropathy by T  lymphocytes 
from B7.2−/− NOD donors (25). In order to address these issues 
in the present model, we investigated whether T-cells from 
ICOSL+/+ or ICOSL−/− NOD donors could transfer diabetes 
or neuromyopathy to conventional NOD.scid or ICOSL−/− 
NOD.scid recipients. As shown in Figure 4A, a significant delay 
was observed in transferring diabetes by CD4+ effector T-cells 
from 40-week-old control ICOSL+/+ into ICOSL−/− as compared 
to ICOSL+/+ NOD.scid recipients. This was the case whatever 
CD4+T-cells were pre-activated in vitro by anti-CD3/anti-CD28 
(Figure 4A) or not (Figure 4B). Strikingly, the transfer of dia-
betes by CD4+CD25− T-cells was totally ineffective in ICOSL−/− 
NOD.scid recipients, indicating that ICOS-ICOSL interaction is 
a prerequisite to the transfer of diabetes by naïve effector CD4+ 
T-cells from diabetic donors (Figure 4C). No significant delay 
was observed when transferring autoimmune neuromyopathy 
by pre-activated CD4+ effector T-cells from ICOSL−/− NOD mice 
into ICOSL−/− NOD.scid recipients as compared to ICOSL+/+ 
NOD.scid recipients (Figure 4D). We thus have evidence that 
ICOS+ T-cells from NOD ICOSL−/− donors that have developed 
autoimmune neuromyopathy can transfer neuromyopathy into 
naïve ICOS+/+ICOSL+/+ NOD.scid as well as ICOS+/+ICOSL−/− 
NOD.scid recipients.
DiscUssiOn
The development of diabetes onto the NOD mouse background 
is associated with many gene variants that are scattered through 
the genome. Many of these susceptibility genes affect pathways 
involved in controlling immune responses (30–32). Among 
regions harboring these genes, one has been identified as carry-
ing genes coding for T lymphocyte costimulatory molecules. A 
region on mouse chromosome 1 (Idd5) that carries costimulatory 
genes has been associated to diabetes in the NOD mouse (33). 
While the Icos−/− strain contains a large non-NOD-derived inter-
val on mouse chromosome 1 containing several genes encoding 
costimulatory molecules genes such as Ctla4, Icos, and Cd28, the 
Icosl−/− strain genome contains almost only NOD alleles on all 
chromosomes and few NOD alleles around the candidate gene 
locus. In addition, this region does neither overlap with known 
Idd candidate regions or QTLs presently known to be involved 
in neuropathy (26). We therefore concentrated our phenotypical 
analysis on the Icosl−/− strain rather than Icos−/− strain.
Beyond inheritance of genes that predispose to general failure 
of immune-tolerance in the NOD mouse, some susceptibility 
regions habour genes that control the targeting or deviation 
of autoimmunity toward or from β-cells, respectively (34). The 
MHC class II I-Ag7 allele that is associated with diabetes is a 
major gene that focuses autoimmunity on the islet (20, 24, 35). 
Beyond class II genes, other genes and environmental factors 
have been shown to deviate autoimmunity from β-cells toward 
other tissues (21, 23, 36). However, there has been so far no 
example of autoimmune deviation from β-cells toward skeletal 
muscles.
The diabetes protective phenotype observed in ICOS−/− and 
ICOSL−/− NOD mice thus indicates that the ICOS/ICOSL 
pathway is directly involved in the T  cell activation observed 
in autoimmune diabetes. ICOSL is constitutively expressed on 
B cells, dendritic cells, and macrophages. It is not expressed on 
T-cells that, however, show lasting intrinsic alterations in transfer 
experiments. ICOS+T-cells that develop in an ICOSL− environ-
ment maintain the capacity to induce a neuromyopathy even in 
an ICOSL sufficient environment. As previously reported, it is 
likely that a turning point in autoimmune activation in the NOD 
mouse takes place within a narrow window around 3  weeks 
of age (1, 37). That may apply to the activation of nerve- and 
muscle-specific T  lymphocytes in ICOSL−/− NOD mice. A 
striking observation in ICOSL−/−, as well as in ICOS−/− NOD 
mice, is the deviation of autoimmunity from the islets toward 
muscles and peripheral nerves. T-cells are predominant among 
the different cell types observed within the infiltrates. Infiltrates 
of similar extent are observed in ICOS−/−ICOSL−/− double-
knockout NOD mice, which fit with previous reports of a single 
ICOS ligand. Finally, neuromuscular autoimmunity develops in 
ICOSL−/− NOD mice within a time frame that is comparable to 
that of diabetes in conventional ICOSL+/+ NOD mice. However, 
the prevalence of neuromyopathy reaches 100% in female mice, 
which we never observed in case of diabetes in conventional 
female NOD mice.
Another example of the shift from diabetes to peripheral nerve 
autoimmunity has been evidenced in B7.2−/− NOD mice in which 
myelin protein 0 has been identified as an auto-antigen (38). 
Autoimmune deviation in ICOSL−/− NOD mice targets muscles 
and peripheral nerves, while it is restricted to peripheral neurons 
in B7.2−/− NOD mice (14, 25). ICOS is expressed on T-cells 
after CD28/B7 engagement. We can suppose that, in absence of 
CD28/B7 signal, ICOS is weakly expressed in B7.2−/− NOD mice 
FigUre 4 | icOs/icOsl signal is not required for efficient transfer of neuromyopathy. (a–c) Eight-week-old recipient ICOSL+/+ (⦁, n = 8) or ICOSL−/− 
NOD.scid mice (◾, n = 8) were transferred with 6 × 106 purified SPL cells including CD4+ and CD8+ T-cells from 40-week-old ICOSL+/+ NOD mice activated in vitro 
with anti-CD28 and anti-CD3 antibody (a), or with 6 × 106 unactivated purified SPL cells including CD4+ and CD8+ T-cells from 40-week-old ICOSL+/+ NOD mice 
(b), or with 6 × 106 unactivated CD4+CD25− T-cells from 40-week-old ICOSL+/+ NOD mice (c). In (D), ICOSL+/+ (⦁, n = 10) or ICOSL−/− (◾, n = 10) female NOD.scid 
were transferred with 1 × 106 activated CD4+ T-cells from 40-week-old ICOSL−/− NOD mice (Log-Rank Test).
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and that the phenotype is partial, as compared to ICOSL−/− NOD 
mice or ICOS−/− NOD mice. A critical point is that the CD28/
B7 pathway indeed remained unaltered in ICOS−/− NOD mice. 
Autoimmune dilated cardiomyopathy has been reported fol-
lowing disruption of the negative immunoregulatory receptor 
PD-1 in BALB/c mice along with diffuse deposition of IgG on 
the cardiomyocyte surface. Anti-troponin I autoantibodies have 
been identified as key effectors in this model (39, 40). Altogether, 
these observations point to local interactions of T-cells with 
resident cells as central in regulating organ-specific immune 
tolerance.
Finally, many diabetes auto-antigens that have been charac-
terized so far are not strictly β-cell-specific and are expressed 
more generally in neuro-endocrine tissues. It has been reported 
that the glial sheath composed of peri-islet Schwann cells is 
destroyed in the pre-diabetic phase in the NOD mouse in which 
autoantibodies are detected and T-cells are activated against 
glial fibrillary acidic protein, which is predominantly expressed 
in Schwann cells and astrocytes (41). However, NOD mice do 
not spontaneously develop autoimmunity to nervous neuronal 
tissues.
Our data show that different mechanisms are involved in 
diabetes in NOD mice and in neuromuscular autoimmunity 
in ICOSL−/− NOD mice. In the autoimmune neuromyopathy 
observed in ICOSL−/− NOD mice, CD4+ T-cells are exclusive 
effectors as neuromuscular autoimmunity still develops in the 
absence of class I MHC molecules and thus of CD8+ effector 
T-cells. These data indicate that class I MHC molecules are not 
necessary for neuromyopathy development. This is in contrast 
with immune mechanisms involved in diabetes development in 
the conventional NOD mouse, in which the highest efficiency of 
diabetes transfer is observed when both CD4+ and CD8+ T-cells 
are co-injected into naive NOD recipients (3). MHC class II−/− 
NOD mice and MHC class I−/− NOD mice are both protected 
from diabetes (42, 43). It has further been shown that diabetes is 
induced in β2m−/− NOD mice when class I expression is restored 
on β-cells (44). We previously showed in ICOS−/− NOD mice that 
diabetes protection related with defective activation of effector 
T-cells. However, an accelerated form of diabetes was observed 
in BDC2.5 ICOS−/− transgenic NOD mice, indicating both that 
diabetogenic BDC2.5 effectors were ICOS-independent and that 
the ICOS/ICOSL interaction was central in the activation of 
regulatory T-cells. Indeed, CD4+CD25+ regulatory T-cells from 
BDC2.5 ICOS−/− NOD mice were significantly less efficient in 
suppressing the T cell response to a mimotope peptide than con-
trol regulatory T-cells in vitro (14). Similarly, we observed herein 
a decrease in relative and absolute numbers of CD4+FOXP3+ 
T-cells in SPL and pancreatic lymph nodes in ICOSL−/− NOD 
mice. Cytokine patterns show that CD4+ T-cells present in muscle 
and nerve infiltrate of ICOSL−/− NOD mice are biased toward a 
Th1 profile with high IFN-γ secretion. In this line, a previous 
study of inflammatory myopathies in patients evidenced the 
crucial role of ICOSL in inducing CD4+ T-cell responses (both 
Th1 and Th2), which could be suppressed in vitro by using an 
anti-ICOSL antibody (45).
Our transfer experiments show that neuromyopathy is effi-
ciently transferred in NOD.scid recipients that express ICOSL 
or not. This suggests that neuromyopathogenic T-cells that have 
developed in the absence of ICOSL remain ICOSL-independent 
in the periphery, in contrast to diabetogenic T-cells that are 
ICOS-dependent. Therefore, naïve diabetogenic T-cells need 
ICOS/ICOSL signal to be activated and to transfer diabetes.
Events that link muscle and nerve autoimmunity remain 
an open issue in ICOS−/− and ICOSL−/− NOD mice. We never 
observed mice in which autoimmune responses to muscle and 
nerve were dissociated. One possibility that will require further 
assessment is that common auto-antigens are targeted by the auto-
immune response in muscle and nerve. A related possibility is that 
distinct isoforms of the same auto-antigen are targeted. Damage 
in either muscles or nerves would then develop as a spreading of 
autoimmunity to epitope that would be shared with the primary 
auto-antigen against which the autoimmune response develops. 
This second possibility would require determining what tissue is 
the primary target of the autoimmune response that develops in 
the absence of ICOS/ICOSL signaling.
In conclusion, while ICOS−/− or ICOSL−/− NOD mice are pro-
tected from T1D, they develop autoimmunity against neural and 
muscular tissues, indicating that ICOS-ICOSL interactions are 
important in polarizing NOD autoimmunity. Neuromyopathy 
is CD4+/MHC class II-dependent and show a Th1 pattern. This 
model should be helpful for identifying new biomarkers in idi-
opathic forms of peripheral nerve and muscular autoimmunity 
and provides the first mouse model of spontaneous autoimmune 
myopathy akin to human myositis.
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